"We are pursuing a very clear strategic path and wish to expand our expertise in the Life Science division further. The acquisition of the remaining approximately 50% of the shares in AJ Roboscreen allows us to meet the requirement of combining our expertise in molecular diagnostics and protein analytics with the expertise in the Group," said Klaus Berka, CEO of Analytik Jena AG.
In the future, in the Life Science growth segment, Analytik Jena wants to direct its focus more on the business with reagents, whereby the closer integration of the Leipzig-based subsidiary AJ Roboscreen GmbH is to play a central role. AJ Roboscreen GmbH develops diagnostic kits, reagents, fine chemicals and disposable consumables for the standardized purification and detection of nucleic acids as well as for detecting specific proteins. Admittedly, the diagnostics of neurodegenerative diseases, such as Parkinson’s or Alzheimer’s, still encompass a comparatively small market. However, in the long term, they harbor enormous potential.